Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway

  1. Hyae Yon Kweon
  2. Mi-Ni Lee  Is a corresponding author
  3. Max Dorfel
  4. Seungwoon Seo
  5. Leah Gottlieb
  6. Thomas PaPazyan
  7. Nina McTiernan
  8. Rasmus Ree
  9. David Bolton
  10. Andrew Garcia
  11. Michael Flory
  12. Jonathan Crain
  13. Alison Sebold
  14. Scott Lyons
  15. Ahmed Ismail
  16. Elaine Marchi
  17. Seong-keun Sonn
  18. Se-Jin Jeong
  19. Sejin Jeon
  20. Shinyeong Ju
  21. Simon J Conway
  22. Taesoo Kim
  23. Hyun-Seok Kim
  24. Cheolju Lee
  25. Tae-Young Roh
  26. Thomas Arnesen
  27. Ronen Marmorstein
  28. Gootaeg Oh  Is a corresponding author
  29. Gholson J Lyon  Is a corresponding author
  1. Ewha Womans University, Republic of Korea
  2. Korea Research Institute of Bioscience and Biotechnology, Republic of Korea
  3. Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, United States
  4. Perelman School of Medicine, University of Pennsylvania, United States
  5. University of Bergen, Norway
  6. Department of Molecular Biology, New York State Institute for Basic Research in Developmental Disabilities, United States
  7. New York State Institute for Basic Research in Developmental Disabilities, United States
  8. Washington University School of Medicine, United States
  9. Korea Institute of Science and Technology, Republic of Korea
  10. Indiana University School of Medicine, United States
  11. Pohang University of Science and Technology, Republic of Korea
  12. George A Jervis Clinic, New York State Institute for Basic Research in Developmental Disabilities, United States

Abstract

Amino-terminal acetylation is catalyzed by a set of N-terminal acetyltransferases (NATs). The NatA complex (including X-linked Naa10 and Naa15) is the major acetyltransferase, with 40-50% of all mammalian proteins being potential substrates. However, the overall role of amino-terminal acetylation on a whole-organism level is poorly understood, particularly in mammals. Male mice lacking Naa10 show no globally apparent in vivo amino-terminal acetylation impairment and do not exhibit complete embryonic lethality. Rather Naa10 nulls display increased neonatal lethality, and the majority of surviving undersized mutants exhibit a combination of hydrocephaly, cardiac defects, homeotic anterior transformation, piebaldism and urogenital anomalies. Naa12 is a previously unannotated Naa10-like paralogue with NAT activity that genetically compensates for Naa10. Mice deficient for Naa12 have no apparent phenotype, whereas mice deficient for Naa10 and Naa12 display embryonic lethality. The discovery of Naa12 adds to the currently known machinery involved in amino-terminal acetylation in mice.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.Mass spectrometry data were uploaded to PRIDE under Project Name: Naa10 mutant mouse N-terminome LC-MS, Project accession: PXD026410.

The following data sets were generated

Article and author information

Author details

  1. Hyae Yon Kweon

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  2. Mi-Ni Lee

    Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Seoul, Republic of Korea
    For correspondence
    minilee@kribb.re.kr
    Competing interests
    The authors declare that no competing interests exist.
  3. Max Dorfel

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Seungwoon Seo

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  5. Leah Gottlieb

    Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Thomas PaPazyan

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Nina McTiernan

    Department of Biomedicine, University of Bergen, Bergen, Norway
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1749-6933
  8. Rasmus Ree

    Department of Biomedicine, University of Bergen, Bergen, Norway
    Competing interests
    The authors declare that no competing interests exist.
  9. David Bolton

    Department of Molecular Biology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Andrew Garcia

    Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Michael Flory

    Research Design and Analysis Service, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Jonathan Crain

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alison Sebold

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Scott Lyons

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Ahmed Ismail

    Genetics, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Elaine Marchi

    Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States
    Competing interests
    The authors declare that no competing interests exist.
  17. Seong-keun Sonn

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  18. Se-Jin Jeong

    Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6375-5334
  19. Sejin Jeon

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3819-3421
  20. Shinyeong Ju

    Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5483-4690
  21. Simon J Conway

    Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianopolis, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Taesoo Kim

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3902-1058
  23. Hyun-Seok Kim

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  24. Cheolju Lee

    Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8482-4696
  25. Tae-Young Roh

    Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5833-0844
  26. Thomas Arnesen

    Department of Biomedicine, University of Bergen, Bergen, Norway
    Competing interests
    The authors declare that no competing interests exist.
  27. Ronen Marmorstein

    Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4373-4752
  28. Gootaeg Oh

    Department of Life Science and College of Natural Sciences,, Ewha Womans University, Seoul, Republic of Korea
    For correspondence
    gootaeg@ewha.ac.kr
    Competing interests
    The authors declare that no competing interests exist.
  29. Gholson J Lyon

    Human Genetics, George A Jervis Clinic, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States
    For correspondence
    gholsonjlyon@gmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5869-0716

Funding

National Research Foundation of Korea (2020R1A3B2079811)

  • Gootaeg Oh

Norwegian Cancer Society (PR-2009-0222)

  • Thomas Arnesen

National Research Foundation of Korea (2017RIDIAB03032286)

  • Mi-Ni Lee

National Research Foundation of Korea (2020RICIC1007686)

  • Mi-Ni Lee

National Institute of General Medical Sciences (R35GM133408)

  • Gholson J Lyon

National Institute of General Medical Sciences (R35GM118090)

  • Ronen Marmorstein

Research Council of Norway (Project 249843)

  • Thomas Arnesen

National Institutes of Health (Project 249843)

  • Simon J Conway

Norwegian Health Authorities of Western Norway (912176)

  • Thomas Arnesen

Norwegian Health Authorities of Western Norway (F-12540-D11382)

  • Thomas Arnesen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Hening Lin, Cornell University, United States

Ethics

Animal experimentation: All experiments were performed in accordance with guidelines of International Animal Care and Use Committee (IACUC) of Ewha Womans University (protocol #18 012)012), Cold Spring Harbor L aboratory (CSHL) protocol # 579961 18 , and Institute for Basic Research in Developmental Disabilities (IBR) (protocol #456).

Version history

  1. Preprint posted: December 20, 2020 (view preprint)
  2. Received: December 20, 2020
  3. Accepted: August 5, 2021
  4. Accepted Manuscript published: August 6, 2021 (version 1)
  5. Accepted Manuscript updated: August 11, 2021 (version 2)
  6. Version of Record published: August 19, 2021 (version 3)

Copyright

© 2021, Kweon et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,216
    views
  • 160
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hyae Yon Kweon
  2. Mi-Ni Lee
  3. Max Dorfel
  4. Seungwoon Seo
  5. Leah Gottlieb
  6. Thomas PaPazyan
  7. Nina McTiernan
  8. Rasmus Ree
  9. David Bolton
  10. Andrew Garcia
  11. Michael Flory
  12. Jonathan Crain
  13. Alison Sebold
  14. Scott Lyons
  15. Ahmed Ismail
  16. Elaine Marchi
  17. Seong-keun Sonn
  18. Se-Jin Jeong
  19. Sejin Jeon
  20. Shinyeong Ju
  21. Simon J Conway
  22. Taesoo Kim
  23. Hyun-Seok Kim
  24. Cheolju Lee
  25. Tae-Young Roh
  26. Thomas Arnesen
  27. Ronen Marmorstein
  28. Gootaeg Oh
  29. Gholson J Lyon
(2021)
Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway
eLife 10:e65952.
https://doi.org/10.7554/eLife.65952

Share this article

https://doi.org/10.7554/eLife.65952

Further reading

    1. Developmental Biology
    Edgar M Pera, Josefine Nilsson-De Moura ... Ivana Milas
    Research Article

    We previously showed that SerpinE2 and the serine protease HtrA1 modulate fibroblast growth factor (FGF) signaling in germ layer specification and head-to-tail development of Xenopus embryos. Here, we present an extracellular proteolytic mechanism involving this serpin-protease system in the developing neural crest (NC). Knockdown of SerpinE2 by injected antisense morpholino oligonucleotides did not affect the specification of NC progenitors but instead inhibited the migration of NC cells, causing defects in dorsal fin, melanocyte, and craniofacial cartilage formation. Similarly, overexpression of the HtrA1 protease impaired NC cell migration and the formation of NC-derived structures. The phenotype of SerpinE2 knockdown was overcome by concomitant downregulation of HtrA1, indicating that SerpinE2 stimulates NC migration by inhibiting endogenous HtrA1 activity. SerpinE2 binds to HtrA1, and the HtrA1 protease triggers degradation of the cell surface proteoglycan Syndecan-4 (Sdc4). Microinjection of Sdc4 mRNA partially rescued NC migration defects induced by both HtrA1 upregulation and SerpinE2 downregulation. These epistatic experiments suggest a proteolytic pathway by a double inhibition mechanism:

    SerpinE2 ┤HtrA1 protease ┤Syndecan-4 → NC cell migration.

    1. Developmental Biology
    2. Neuroscience
    Kristine B Walhovd, Stine K Krogsrud ... Didac Vidal-Pineiro
    Research Article

    Human fetal development has been associated with brain health at later stages. It is unknown whether growth in utero, as indexed by birth weight (BW), relates consistently to lifespan brain characteristics and changes, and to what extent these influences are of a genetic or environmental nature. Here we show remarkably stable and lifelong positive associations between BW and cortical surface area and volume across and within developmental, aging and lifespan longitudinal samples (N = 5794, 4–82 y of age, w/386 monozygotic twins, followed for up to 8.3 y w/12,088 brain MRIs). In contrast, no consistent effect of BW on brain changes was observed. Partly environmental effects were indicated by analysis of twin BW discordance. In conclusion, the influence of prenatal growth on cortical topography is stable and reliable through the lifespan. This early-life factor appears to influence the brain by association of brain reserve, rather than brain maintenance. Thus, fetal influences appear omnipresent in the spacetime of the human brain throughout the human lifespan. Optimizing fetal growth may increase brain reserve for life, also in aging.